We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$356M
AUM Growth
+$69.2M
Cap. Flow
+$89M
Cap. Flow %
25.02%
Top 10 Hldgs %
43.39%
Holding
101
New
33
Increased
27
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$23M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.27M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$8.98M
4
KRYS icon
Krystal Biotech
KRYS
+$7.02M
5
ACLX
Arcellx
ACLX
+$5.99M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$12.3M
2
BIIB icon
Biogen
BIIB
+$11.4M
3
VTYX
Ventyx Biosciences
VTYX
+$3.3M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$2.97M
5
KYNB
Kyntra Bio
KYNB
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 81.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSP icon
51
Inspire Medical Systems
INSP
$1.42B
$1.25M 0.35%
+6,293
New +$1.59M
EYPT icon
52
PUT
EyePoint Inc
EYPT
$1.02B
$1.24M 0.35%
+155,000
New +$1.7M
NAMS icon
53
NewAmsterdam Pharma
NAMS
$3.47B
$1.16M 0.33%
125,000
+25,000
+25% +$271K
MORF
54
PUT
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.15M 0.32%
+50,000
New +$2.62M
TRML
55
DELISTED
Tourmaline Bio
TRML
$1.12M 0.32%
40,000
+20,000
+100% +$586K
THRX
56
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$1.08M 0.3%
400,726
+160,482
+67% +$629K
MIST icon
57
Milestone Pharmaceuticals
MIST
$144M
$1.04M 0.29%
335,068
+35,000
+12% +$109K
LIAN
58
DELISTED
LianBio American Depositary Shares
LIAN
$1M 0.28%
672,357
-128,319
-16% -$244K
ADCT icon
59
ADC Therapeutics
ADCT
$146M
$987K 0.28%
1,100,000
+500,000
+83% +$665K
IFRX icon
60
InflaRx
IFRX
$256M
$969K 0.27%
325,097
+84,897
+35% +$323K
SWTX
61
DELISTED
SpringWorks Therapeutics
SWTX
$961K 0.27%
41,581
-88,419
-68% -$2.42M
MIRM icon
62
Mirum Pharmaceuticals
MIRM
$6.89B
$948K 0.27%
30,000
– –
TVTX icon
63
Travere Therapeutics
TVTX
$5.33B
$894K 0.25%
+100,000
New +$1.41M
PODD icon
64
Insulet
PODD
$11.3B
$797K 0.22%
+5,000
New +$1.12M
BBIO icon
65
BridgeBio Pharma
BBIO
$16.5B
$791K 0.22%
30,000
-5,133
-15% -$146K
BHVN icon
66
Biohaven
BHVN
$2.16B
$784K 0.22%
+30,156
New +$627K
TECX
67
Tectonic Therapeutic
TECX
$573M
$770K 0.22%
+41,667
New +$737K
IMTXW
68
DELISTED
Immatics N.V. Warrants
IMTXW
$663K 0.19%
187,204
– –
ETNB
69
CALL
DELISTED
89bio
ETNB
$576K 0.16%
+37,300
New +$626K
PBYI icon
70
Puma Biotechnology
PBYI
$406M
$532K 0.15%
202,349
– –
PMN icon
71
ProMIS Neurosciences
PMN
$109M
$527K 0.15%
+10,638
New +$691K
CNTX icon
72
Context Therapeutics
CNTX
$56.4M
$497K 0.14%
328,817
+61,243
+23% +$69.3K
MESO
73
PUT
Mesoblast
MESO
$1.99B
$492K 0.14%
+200,000
New +$956K
NUVB icon
74
Nuvation Bio
NUVB
$2.24B
$335K 0.09%
250,000
– –
BCAB icon
75
BioAtla
BCAB
$5.59M
$306K 0.09%
3,600
-2,900
-45% -$370K
1 2
3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return

Affinity Asset Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Affinity Asset Advisors held 101 positions worth $356M, up 24% from $286M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $89M of net new capital in Q3 2023, opening 33 new positions and adding to 27 existing holdings. Its largest new stake was Apogee Therapeutics: 1,045,110 shares worth $22.3M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $2.42M trimmed.

  • Affinity Asset Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,045,110 shares worth $22.3M.
  • Affinity Asset Advisors added most to Xenon Pharmaceuticals in Q3 2023, an estimated $8.98M increase.
  • Affinity Asset Advisors's biggest Q3 2023 reduction was SpringWorks Therapeutics, cutting an estimated $2.42M.
  • Affinity Asset Advisors fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $12.3M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $356M portfolio in Q3 2023.
  • Affinity Asset Advisors opened 33 new positions and closed 20 in Q3 2023.
  • Affinity Asset Advisors's portfolio value rose 24% quarter-over-quarter to $356M.

Based on Affinity Asset Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.